Second Transplant for Relapsed AML, Learning from Defeat

In patients with acute myeloid leukemia (AML), the development of recurrent disease after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a dismal prognosis. Commonly used strategies such as the withdrawal of immunosuppressive agents, the use of targeted molecules or chemotherapy, donor lymphocyte infusion (DLI), or a second transplant (HSCT2) can benefit only the selected few. Therefore, it is critical to identify subsets of patients who derive the most benefit from a specific salvage approach.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: The Bottom Line Source Type: research